Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board:
Last Post: 8/20/2014 11:41:37 PM - Followers: 1093 - Board type: Free - Posts Today: 0
PostSubject
#181353  Sticky Note This Tekmira publication likely reads through to Ebola: biomaven0 08/20/14 03:03:15 PM
#181341  Sticky Note WSJ Editorial -- Medical Innovation Threat steveporsche 08/20/14 11:25:37 AM
#181338  Sticky Note ILMN FMI AFFX> Flatley's Law: How One Company biocqr 08/20/14 10:26:08 AM
#181337  Sticky Note FOLD’s second attempt on Migalastat hits primary endpoint: DewDiligence 08/20/14 09:30:15 AM
#181334  Sticky Note FDA Approves Genzyme’s Cerdelga™ (eliglustat) Capsules genisi 08/20/14 07:25:23 AM
#180080  Sticky Note What is your view on RGDO?From day one, DewDiligence 07/03/14 11:44:16 AM
#181366   The Risky Business of Limiting Medicaid Access to Sovaldi caravon 08/20/14 11:41:37 PM
#181365   AZN> You know what IV that represented? biocqr 08/20/14 08:35:26 PM
#181364   >> If this is just a straight up jq1234 08/20/14 07:19:36 PM
#181363   Re; ARRY/NVS and potential return of MEK162 exwannabe 08/20/14 06:54:16 PM
#181362   Five AMPH directors made small open-market purchases of DewDiligence 08/20/14 06:16:36 PM
#181361   ARRY’s 2Q14 PR says ARRY expects NVS to DewDiligence 08/20/14 05:58:53 PM
#181360   >>10K Oct 65 puts traded @ $1.. AZN biomaven0 08/20/14 05:34:05 PM
#181359   >reads through to Ebola biomaven0 08/20/14 05:07:57 PM
#181358   Do you have any thoughts on how much ghmm 08/20/14 04:37:09 PM
#181357   SIGA 1.40 / NLNK 24.02 - Two backdoor RNsidersbuying 08/20/14 04:31:36 PM
#181356   $FOLD Janney Capital Sees 42% Upside In Amicus maytepper 08/20/14 03:15:48 PM
#181354   reads through to EbolaWhat do you mean exactly? GrthzGd 08/20/14 03:11:02 PM
#181353   This Tekmira publication likely reads through to Ebola: biomaven0 08/20/14 03:03:15 PM
#181352   Is 8-weeks of S/L non-inferior to 12-weeks of DewDiligence 08/20/14 02:53:38 PM
#181351   It would help if we knew the price oc631 08/20/14 02:51:35 PM
#181350   Market can solve everything until it can't.It should GrthzGd 08/20/14 02:51:30 PM
#181349   If GILD raises the price of standalone Sovaldi, DewDiligence 08/20/14 02:41:59 PM
#181348   MON webcast slides from today’s “whistle stop” event DewDiligence 08/20/14 02:39:12 PM
#181347   GILD’s response to the Congressional questions is technically DewDiligence 08/20/14 02:36:55 PM
#181346   The health insurers say they merely want to biotech jim 08/20/14 02:32:10 PM
#181345   $FLML Roth Capital Recommends Purchase Flamel Shares Ahead maytepper 08/20/14 02:30:14 PM
#181343   >> The claim by the insurance industry and jq1234 08/20/14 01:34:50 PM
#181342   $CYTX Roth Capital Reiterates Buy On Cytori After maytepper 08/20/14 01:15:00 PM
#181341   WSJ Editorial -- Medical Innovation Threat steveporsche 08/20/14 11:25:37 AM
#181340   AZN > My option scan shows 10K Oct biocqr 08/20/14 11:09:22 AM
#181339   This is a must read article: Flatley's Law: biotech_researcher 08/20/14 11:03:20 AM
#181338   ILMN FMI AFFX> Flatley's Law: How One Company biocqr 08/20/14 10:26:08 AM
#181337   FOLD’s second attempt on Migalastat hits primary endpoint: DewDiligence 08/20/14 09:30:15 AM
#181336   BMY, CELG ink clinical collaboration to test Opdivo DewDiligence 08/20/14 09:26:43 AM
#181335   NTRP - Neurotrope’s Approach to Treating Alzheimer’s Disease iandy 08/20/14 08:18:36 AM
#181334   FDA Approves Genzyme’s Cerdelga™ (eliglustat) Capsules genisi 08/20/14 07:25:23 AM
#181333   NVS/Gamida-cell Finally! (and a more cautious deal from NVS side, genisi 08/20/14 05:53:47 AM
#181332   This doesn't take into account the difference in oc631 08/19/14 10:28:02 PM
#181331   ONTY - What astounds me is that they hirogen 08/19/14 10:19:23 PM
#181330   NVS acquires 15% stake/buyout option on Israeli stem-cell mcbio 08/19/14 09:45:04 PM
#181329   AQXP - $18M EV and big pharma backing gftb5 08/19/14 07:36:52 PM
#181328   Re: Sovaldi pricing and 3rd party combos. exwannabe 08/19/14 06:14:12 PM
#181327   We were talking about raising the price oc631 08/19/14 04:45:00 PM
#181326   ONTY - Apparently Merck decided this was too iwfal 08/19/14 01:02:05 PM
#181324   ONTY - All told - I'd interpret this hirogen 08/19/14 12:47:23 PM
#181323   >> The idea of raising the price of jq1234 08/19/14 12:08:40 PM
#181322   Remember a bidding war for Amlyn with a frontiers 08/19/14 11:58:42 AM
#181321   I expect the Achn buyout will happen at caravon 08/19/14 11:04:38 AM
#181320   NVS acquires 15% stake/buyout option on Israeli stem-cell DewDiligence 08/19/14 10:34:15 AM
#181319   BTW, all these trials -- GS-7977 (sovaldi), IDIX frontiers 08/19/14 10:26:35 AM
#181318   >>Is there any chance this stuff would work biomaven0 08/19/14 09:42:34 AM
#181316   GS 7977 (sovaldi) followed the same route -- frontiers 08/19/14 09:31:53 AM
#181315   Thus raising the price for GT2/GT3 patients.By DewDiligence 08/19/14 09:28:48 AM
#181314   LOL—I had to check to make sure it DewDiligence 08/19/14 09:19:50 AM
#181313   Pricing issue for Sovaldi itself will be moot oc631 08/19/14 06:35:04 AM
PostSubject